Medical Condition News

RSS

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury.

8 Apr 2010

Pair of proteins excreted in urine could lead to earlier diagnosis of kidney cancer: Researchers

Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.

8 Apr 2010

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll up to an additional 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Obstructive sleep apnea associated with increased risk of stroke in men

Obstructive sleep apnea is associated with an increased risk of stroke in middle-aged and older adults, especially men, according to new results from a landmark study supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

8 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Transcendental Meditation may reduce symptoms of depression

The Transcendental Meditation- technique may be an effective approach to reduce symptoms of depression, according to two new studies to be presented at the 31st Annual Meeting of the Society of Behavioral Medicine in Seattle, Washington April 9th, 2010.

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya's IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).

8 Apr 2010

Ultrasound scan of carotid artery improves prediction of heart disease: Research

New research shows that doing a simple ultrasound scan of the carotid artery significantly improves the prediction of heart disease, giving doctors a better clue of who is at high risk for a heart attack.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18

Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.

8 Apr 2010

Scientists discover how mechanical stress promotes new bone growth

For osteoporosis patients unable to exercise, help may be on the way. That's because scientists have discovered precisely how mechanical stress, such as exercise, promotes new bone growth. This opens the door to entirely new therapies that can trick bones into thinking they are getting a workout. The research report describing this advance is published online in The FASEB Journal.

8 Apr 2010

Study: New endoscopic spray may offer surgery-free procedure for acute bleeding of peptic ulcers

According to early clinical evidence from a safety study, a new endoscopic spray from Cook Medical may offer a new surgery-free procedure for treating potentially fatal acute bleeding of peptic ulcers.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

Torax Medical's LINX Anti-Reflux treatment receives CE Mark approval

Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease (GERD), has received CE Mark for its LINX® Anti-Reflux treatment. The company has started commercial launch of the LINX device at select centers in Europe.

8 Apr 2010

Is grandmother’s age significant to autism?

A report just published in the online journal, PLoS ONE, indicates that the mothers of children with an autistic spectrum disorder were themselves more likely to have been born to older mothers. These findings could open up new avenues in autism research.

8 Apr 2010

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

ASPIRE 2010 focuses on A.R.T. issues

Infertility, defined as the failure to conceive after 12 months or more of regular, unprotected intercourse, may affect as many as 15 percent of couples around the world including Asia. Like other countries, China's infertility rate is on the rise increasing from 3 percent to 15 percent in the past 20 years. It is estimated that at least 40 million Chinese couples have difficulty in having children or are actually infertile.

7 Apr 2010

Medical Condition News

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Pair of proteins excreted in urine could lead to earlier diagnosis of kidney cancer: Researchers

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Obstructive sleep apnea associated with increased risk of stroke in men

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Transcendental Meditation may reduce symptoms of depression

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Ultrasound scan of carotid artery improves prediction of heart disease: Research

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18

Scientists discover how mechanical stress promotes new bone growth

Study: New endoscopic spray may offer surgery-free procedure for acute bleeding of peptic ulcers

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Torax Medical's LINX Anti-Reflux treatment receives CE Mark approval

Is grandmother’s age significant to autism?

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

ASPIRE 2010 focuses on A.R.T. issues

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News